BioAgilytix Secures Significant New Investment from Global Investor Cinven to Fuel Continued Long-Term Growth

BioAgilytix, a leading global contract research organization (CRO), today announced an agreement to be further capitalized by Cinven, a leading international private investment firm focused on building world-class global companies. Cinven will acquire a majority stake in BioAgilytix while current majority investor Cobepa, S.A., a Brussels-based private investment firm, will remain a significant minority investor in the Company.
（以上内容由医药魔方AI生成）